Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why TherapeuticsMD Jumped 25.6% in September

By Maxx Chatsko - Oct 7, 2019 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The path ahead is looking a bit brighter for this pharmaceutical company.

What happened

Shares of TherapeuticsMD ( TXMD 4.51% ) gained more than 25% last month, according to data provided by S&P Global Market Intelligence. The pharmaceutical company, which focuses on women's health, published an investor update in mid-September reporting solid progress for its drug portfolio. 

According to that update, large insurance companies are continuing to add the company's drug products to their coverage lists, Imvexxy maintained prescription momentum in August, and the CEO bought $280,000 in stock in the third quarter. All of those points contributed to investor optimism that pushed shares of the pharmaceutical company higher again after they hit a more-than-five-year low in early August. (They remain, however, about 40% below their 12-month peak.)

A businessman drawing an ascending yellow step chart.

Image source: Getty Images.

So what

TherapeuticsMD is still in the early stages of commercializing its treatments. The business reported just $6.1 million in revenue in the second quarter, and current full-year guidance is for revenue of at least $29.4 million. But the company has three drugs on the market with ample growth potential.

Imvexxy (launched in August 2018), Bijuva (launched in April 2019), and Annovera (launching in Q1 2020) have combined peak annual sales potential of $1.85 billion. It will take time to get those drugs covered by major insurance programs, navigate the patchwork system of state laws relating to women's health, and increase awareness about the new treatments among doctors and the patients who could potentially benefit from them. However, TherapeuticsMD appears to be making progress.

Now what

Investors are growing more optimistic about the company's ability to ramp up sales in the near future, but it might be best to keep expectations in check. Growing prescriptions for a new drug is expensive -- the company burned through $88.7 million in cash in the first half of 2019 -- and TherapeuticsMD's offerings are competing against a number of other treatment options. If progress occurs too slowly, investors could lose their taste for the money-losing enterprise, especially if it reaches the point where it needs to raise more cash.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TherapeuticsMD, Inc. Stock Quote
TherapeuticsMD, Inc.
TXMD
$0.46 (4.51%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.